Novo Nordisk A/S is back on the hunt for deals to boost its obesity portfolio after losing US biotech Metsera Inc. in a ...

After a period of diversification, Novo Nordisk is returning to its roots by focusing on the 2 billion people with diabetes, ...

Novo Nordisk's new chief executive, Mike Doustdar, has told the JPM Healthcare conference that the key to competing in the GLP-1 agonist category for weight loss will be to make the most of cash-pay ...

The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out ...

Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions of ...

Novo Nordisk CEO Mike Doustdar said on Tuesday the drugmaker expects headwinds in its international operations in 2026, as ...

Maziar Mike Doustdar, the new president and chief executive of Danish pharma major Novo Nordisk, had the chance to set out ...

CEO Mike Doustdar shared the figure Monday at the J.P. Morgan Healthcare Conference, saying compounded versions have gained ...

Novo Nordisk CEO Mike Doustdar anticipates headwinds by 2026 in international operations due to increased competition after ...

Novo Nordisk CEO Mike Doustdar highlighted the growing use of compounded GLP-1 drugs in the U.S., which are cheaper but ...

Obesity took center stage on the first day of the 2026 J.P. Morgan Healthcare Conference, with industry frontrunners Eli ...

Investing.com -- Novo Nordisk CEO Mike Doustdar said the company faces headwinds in its international operations in 2026 as competition increases following the loss of market exclusivity in several ...